✦ LIBER ✦

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

✍ Scribed by Alessandra Fabi, Michelangelo Russillo, Gianluigi Ferretti, Giulio Metro, Cecilia Nisticò, Paola Papaldo, Ferdinando De Vita, Giuliana D’Auria, Antonello Vidiri, Diana Giannarelli, Francesco Cognetti

Book ID: 119897519
Publisher: BioMed Central
Year: 2012
Tongue: English
Weight: 188 KB
Volume: 12
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-12-482

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

487 Efficacy of first-line capecitabine

487 Efficacy of first-line capecitabine plus bevacizumab in patients with ER/PgR-positive metastatic breast cancer (MBC) and those previously treated with hormone therapy

✍ V. Diéras; V. Semiglazov; S. Tjulandin 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

417 POSTER Maintenance hormone therapy w

417 POSTER Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 136 KB

470 Final results of a phase II study of

470 Final results of a phase II study of combination with nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy in patients with HER2-negative metastatic breast cancer

✍ S. Glück; C. Lobo; G. Lopes; A. Castrellon; J. Hurley; I. Reis; S. Richman; O. S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Final results of a phase II study ofnab-

Final results of a phase II study ofnab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

✍ Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Fe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 268 KB

Nanoparticle albumin-bound paclitaxel in

Nanoparticle albumin-bound paclitaxel in 3 dosing schedules with bevacizumab as first line therapy for HER2-negative metastatic breast cancer: an interim safety analysis

✍ A.D. Seidman; A.K. Conlin; M.E. Moynahan; A. Bach; T. Troso-Sandoval; S. Sugarma 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 63 KB

5074 First-line bevacizumab (bev) plus p

5074 First-line bevacizumab (bev) plus paclitaxel (pac) combination therapy: safety findings (n = 165) from a multicentre German non-interventional study in patients with metastatic breast cancer (MBC)

✍ F. Foerster; M. Geberth; C. Schumacher; A. Schneeweiss; R. Weinberg; L. Hahn; M. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB